# Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

> **NCT00772382** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 116 (actual)

## Conditions studied

- Chronic Kidney Disease
- Dialysis
- Hyperphosphatemia

## Interventions

- **DRUG:** MCI-196

## Key facts

- **NCT ID:** NCT00772382
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00772382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00772382, "Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00772382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*